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In spinal cord repair, the challenge consists in combining various therapies that account for
multiple deleterious effects in order to induce an efﬁcient recovery. In that context,
biomaterial implantation seems to be highly relevant. Indeed, biomaterials not only serve
as a growth support to promote sectioned axonal ﬁbers, but are also used for cell trans-
plantation and drug delivery. In this review, we discuss and put into perspective the recent
results obtained in the ﬁeld of spinal cord repair by synthetic hydrogel implantation. The
versatility of those biomaterials is presented through the latest chemical strategies
developed to enhance their therapeutic effects.
© 2015 Academie des sciences. Published by Elsevier Masson SAS. This is an open access
article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
r é s u m é
Face au deﬁ de la reparation medullaire, une polytherapie visant un grand nombre d’effets
deleteres est susceptible d’entraîner une recuperation importante. Dans ce contexte,
l’implantation de biomateriaux semble e^tre particulierement adaptee. En effet, les bio-
materiaux ne servent pas seulement a fournir un support de repousse pour les axones
leses, mais sont egalement utilises pour la transplantation cellulaire et la liberation de
molecules pharmacologiques. Dans cette revue, nous abordons et mettons en perspective
les derniers developpements obtenus dans le domaine de la reparation medullaire par
l’implantation d’hydrogels synthetiques. La versatilite de ces biomateriaux est presentee
au travers des dernieres strategies developpees pour accroître leurs effets therapeutiques.
© 2015 Academie des sciences. Published by Elsevier Masson SAS. This is an open access
article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).e (AMU) and Centre
R 7273 « Institut de
ganique et Polymeres
cadrille Normandie-
(T. Trimaille), didier.
ed by Elsevier Masson SAS.1. Introduction
The debilitating effects of spinal cord injuries (SCI) are
not only induced by direct disruption of spinal cord
ascending and descending pathways, but also by post-
traumatic complications, known as the second injury,
which in part encompasses ischemia, hematotoxicity,This is an open access article under the CC BY-NC-ND license (http://
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ecules inhibiting axonal regrowth [1]. As a result, both
acute and chronic therapeutic interventions have been
designed to potentiate the limited spontaneous recovery
that is sometimes observed in SCI patients. They usually
consist in limiting secondary injury, promoting plasticity or
axonal regrowth through rehabilitation, cell trans-
plantation [2], or molecule administrations (e.g. neuro-
trophic factors and antagonists for neurite growth
inhibitors) [3]. Although promising results have been ob-
tained in animal studies, no efﬁcient clinical therapy,
except rehabilitation, is yet available [4]. This poor trans-
lation from animal research evidence to effective clinical
treatments could be, in part, caused by the shortcomings of
cell transplantation andmolecule administration. Indeed, it
was noted that a majority of cells undergoes apoptosis after
implantation due to the hostility of the lesion site envi-
ronment and the lack of cell adhesion [5]. In addition, direct
molecule injection leads to uncontrolled molecule release
kinetics [6].
An alternative strategy is to ﬁll the spinal cord cavity
with a polymer biomaterial in order to reduce the glial scar,
which is known to impede axonal regrowth, and to increase
axonal regeneration by supplying a substrate for growth
support [7]. However, to efﬁciently repair the spinal cord
the characteristics of implanted biomaterials should prop-
erly match the ones of the nervous tissue’s extracellular
matrix (ECM) as it was shown that the ECM played a key
role in the migration, the morphology, the phenotype and
the survival of cells [8]. A recent study even demonstrated
that the implantation of an acellular spinal cord scaffold,
obtained through a simple series of detergent, induced
functional recovery in hemisected rats [9]. In that context,
hydrogels, which are three-dimensional networks formed
by hydrophilic cross-linked polymers swollen in water,
seem to be well suited for both spinal cord and brain repair
[10]. Hydrogels can easily be cast into various shapes in
order to properly ﬁll the lesion site or to present pores and
microchannels [11]. Moreover, by adjusting the synthesis
process it is possible to obtain hydrogels with modulus of
elasticity that closely ﬁts the soft mechanical properties of
the nervous tissue [12]. Hydrogelmechanical properties are
not only known to profoundly affect the neuronal
morphology such as neurite branching [13] but also to
regulate the self-renewal and the differentiation of the
neural stem cell (NSC) [14]. In fact, hydrogels are well
suited to be used as cell carriers as it was shown that cells
delivered via a biocompatible scaffold presented high sur-
vival rates than transplanted cells through simple injection
[5].
To date, various polymers from both natural and syn-
thetic origins have already induced therapeutic effects in
different animal models [15e17]. Nevertheless, synthetic
hydrogels are particularly attractive as they present a low
batch-to-batch variability and can bemanipulated to have a
wider range of physico-chemical properties than natural
ones. Additionally, implantation of synthetic materials
avoids disease transmission and reduces allergenic and
immunogenicity risks [16, 18]. Synthetic hydrogels used in
spinal cord repair principally consist of polymethacrylates/
methacrylamides and polyethers whose cross-linking isbased on different chemistry approaches (e.g. radical
polymerization and click reactions). They have been
extensively studied and brought promising results. Indeed,
functional improvement, tissue recovery and axonal
regeneration have been observed after implantation of poly
[N-(2-hydroxypropyl)methacrylamide] (PHPMA) [19],
poly(2-hydroxyethyl methacrylate) (PHEMA) [20], and
poly(ethylene glycol) (PEG) hydrogels, respectively [21].
Although hydrogel implantation induces therapeutic ef-
fects by itself, synergistic outcomes are generally observed
with cell-seeded scaffolds [22]. Indeed, Hejcl et al. only
observed signiﬁcant functional improvement after the
implantation of the mesenchymal stem cell (MSC)-seeded
PHPMA hydrogel in a chronic SCI model [23]. Other authors
studied injectable in situ-forming hydrogels in order to
limit the surgical invasiveness of conventional implanta-
tion [16].
Many well-written reviews already discussed the
therapeutic effects induced by the implantation of bio-
materials after a spinal cord injury [3, 15e17]. In those
reviews, the biomaterials were either classiﬁed depend-
ing on their nature or their characteristics and both ad-
vantages and drawbacks of each biomaterial were
debated. In particular, the review of Straley et al. in 2010
has thoroughly listed the desired characteristics of
hydrogels for use in spinal cord repair. Besides complex
questions about mechanical compliance, adapted
porosity/topography, injectability and cell encapsulation,
the authors pointed out the crucial importance of cell
adhesion, biomolecule delivery and degradability in the
design of hydrogel scaffolds. In this short review, we
precisely focus on the chemical strategies recently
developed to obtain synthetic hydrogels displaying these
three key features for use in spinal cord repair, namely (i)
improved surface biofunctionality regarding cell adhe-
sion, (ii) drug delivery ability, and (iii) degradability
properties so as to avoid chronic complications [3, 18]. We
included both in vivo and in vitro studies on tissue
regeneration obtained with these scaffolds. Although
each section of this review deals with deﬁnite charac-
teristics, it is important to keep in mind that they are all
intertwined.
2. Bioadhesion promoting strategies
In spite of exhibiting the interesting above-mentioned
features, synthetic polymer-based biomaterials do not
generally present inherent surface properties that can
provide a suitable environment for biological processes
(primarily cell adhesion). Therefore, many efforts have
been devoted to modify the bioinert surface of these
biomaterials by ECM proteins (e.g. laminin, ﬁbronectin,
and collagen), which have the speciﬁc advantage of pos-
sessing cell-adhesive or signaling domains. Such strategy
is not only known to increase tissue integration and
viability of transplanted cells but also to improve axonal
regeneration. Indeed, after a complete spinal cord tran-
section, a higher number of regenerating axons were
observed in ﬁbrin-ﬁlled poly(2-hydroxyethyl
methacrylate-co-methyl methacrylate) (PHEMA-MMA)
implanted channels than in unﬁlled channels [24].
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in vitro on the PEG hydrogel coated with ﬁbronectin (i.e.
an ECM glycoprotein) [25]. However, ECM-derived pro-
teins present multiple limitations such as disease trans-
mission, risks of degradation and inadequate adsorption
leading to poor efﬁciency for cell adhesion. Indeed, full-
length ECM proteins might undergo conformational
changes that could induce a foreign body response or
result in the masking of the binding domains needed to
promote the cell adhesion [26]. As a result, studies are
now being increasingly focused on polymer modiﬁcation
with only the biologically active peptide sequences
derived from these ECM molecules, such as the well
known arginine-glycine-aspartic acid (RGD) or isoleucine-
lysine-valine-alanine-valine (IKVAV) [27], that are chemi-
cally well deﬁned and much easier to prepare (automated
peptide synthesis) and handle. Nevertheless, a recent
strategy showed the possibility to speciﬁcally immobilize
full-length proteins so as to retain their active conforma-
tion. This strategy involved polymer surface modiﬁcation
with streptavidin, through the use of a photo-cross-
linkable diazirine agent, and further binding with the
biotinylated protein. Such immobilized protein induced a
superior neurite outgrowth than its analog that was sim-
ply adsorbed on the polymer in a non-controlled manner
[28].
In the context of long-term implants, such as in spinal
cord repair, peptides of interest are preferentially attached
to biomaterials through covalent bindings in order to limit
peptide removal over time [29]. Numerous studies
regarding bioactive peptide functionalization have been
performed on methacrylamide/methacrylate-based
hydrogels, through various approaches. For example, a
PHPMA-RGD hydrogel was synthetized by radical copoly-
merization of HPMA with a methacrylamide-terminated
GGRGD peptide, obtained from reaction of N-terminal
amine of the GGRGD peptide with methacryloyl chloride
[30, 31]. Ethylene dimethacrylate was also used as a
comonomer during the polymerization to induce chain
cross-linking, as well as solid porogen (sodium chloride) to
impart porosity. This speciﬁc hydrogel then was seeded
with MSC before being implanted into a hemisected
thoracic rat spinal cord. As expected, the PHPMA-RGD
hydrogel presented a better combination of properties for
tissue regeneration than the non-functionalized PHPMA
hydrogel (Fig. 1A).
The binding motif can also be incorporated into a post-
polymerization approach, as reported for PHEMA-based
hydrogel analogs. This strategy involves the copolymeri-
zation of HEMA with 2-aminoethyl methacrylate (AEMA),
which displays an amino function usable for the subse-
quent attachment of peptides of interest [32, 33]. In
particular, in recent studies of Kubinova et al., the P(HEMA-
co-AEMA) hydrogel was reacted with g-thiobutyrolactone
to introduce thiol groups (SH), which after activation with
2,20-dithiodipyridine (TPy) immobilized the Ac-
CGGASIKVAVS sequence via the SH groups of cysteine
(Fig. 1B, top pathway). They noted a signiﬁcantly higher
MSC density and cell growth area on Ac-CGGASIKVAVS-
modiﬁed P(HEMA-co-AEMA) than that on PHEMA,
P(HEMA-co-AEMA), P(HEMA-co-AEMA)-SH and P(HEMA-co-AEMA)-TPy hydrogels. Additionally, the data suggest
that the Ac-CGGASIKVAVS-modiﬁcation enhanced the
attachment, proliferation and differentiation of NSCs.
Indeed, after two weeks of culture, only NSCs growing on
the Ac-CGGASIKVAVS-modiﬁed P(HEMA-co-AEMA)
hydrogel formed long processes and displayed a neuron-
like morphology. In a further study, Kubinova et al. noted
in a complete transection model that the implantation of a
similar SIKVAV-modiﬁed PHEMA hydrogel exhibiting ori-
ented pores, obtained by the use of parallel needle-like
ammonium oxalate crystals, allowed axonal ﬁbers to
bridge the spinal cord gap [34]. However, the authors
pointed out that due to the large size of the Ac-
CGGASIKVAVS, it was expected that the peptide did not
penetrate into the hydrogel but mostly remained on its
surface. In a similar approach, thiol-terminated laminin-
derived oligopeptides (CDPGYIGSR and CQAASIKVAV) have
been inserted into hydrogels using a sulfosuccinimidyl 4-
(N-maleimidomethyl)cyclohexane-1-carboxylate (sulfo-
SMCC) approach. While the sulfo-NHS end group of the
sulfo-SMCC reacted with the primary amine groups on the
hydrogel, its maleimide end-group reacted with the oligo-
peptide thiol group (Fig. 1B, bottom pathway). The authors
noticed that this peptide-modiﬁed hydrogel promoted cell
adhesion and neurite outgrowth of primary chick dorsal
root ganglia cells in contrast to P(HEMA-co-AEMA) controls
[33]. The authors noted the importance of introducing
spacers (e.g. additional amino acids) between the biologi-
cally active peptide sequence and the polymer chain to
improve recognition of receptors (integrins) and thus
enhance cellular interactions [35].
Biomolecules other than adhesion peptides were also
introduced in the PHEMA in order to optimize hydrogel
surface properties, using a similar post-polymerization
approach. Ruzicka et al. have synthesized a serotonin-
modiﬁed PHEMA (PHEMA-5HT) hydrogel [36], as this
neurotransmitter has been shown to support cell attach-
ment and to facilitate neuronal differenciation. In the ﬁrst
step, a porous hydrogel was synthesized by the radical
polymerization of HEMA, [2-(methacryloyloxy)ethyl](-
trimethyl) ammonium chloride (PMADQUAT), 2-
aminopropyl methacrylamide hydrochloride (AMPA), and
ethylene glycol dimethacrylate (EGDMA) as a cross-linker
using azobis(isobutyronitrile) (AIBN) as an initiator and
sodium chloride as a porogen. In the second step, after
deprotonation, the pendant primary amino groups of the
resulting gel were allowed to react with PEG diglycidyl
ether, leading to pendant epoxide moieties. The latter were
involved in the reaction with the amino group of the se-
rotonin, leading to the PHEMA-5HT. The authors ﬁrst
observed, in vitro, a positive effect of the PHEMA-5HT
hydrogel on the growth and differentiation of the seeded
cells (i.e. a speciﬁc cell line of fetal NSCs derived from fetal
human spinal cords, namely SPC-01). Then, after having
implanted the SPC-01 cell seeded PHEMA-serotonin
hydrogel into a lateral hemisection cavity, they conﬁrmed
that the cells survived, proliferated and differentiated into
relevant neuronal subtypes. The paracrine effect of those
cells protected the remaining tissue and promoted axonal
regeneration and angiogenesis. Additionally, the polymer
reduced the astrogliosis one month after the injury.
Fig. 1. Chemical approaches for PHPMA/PHEMA hydrogel functionalization with cell adhesion peptides; (A) use of an N-terminus methacrylated peptide (RGD
based sequence) as a comonomer for polymerization; (B) post-polymerization method for coupling of thiol-terminated peptides (IKVAV and YIGSR based se-
quences), based on bifunctional dithiopyridine (top pathway) or sulfo-SMCC (bottom pathway) linkers.
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months after the implantation was explained as a result of
enzymatic degradation of serotonin.
PEG-based hydrogels, as attractive candidates for neural
tissue repair, have been also the focus of numerous studies
regarding peptide functionalization for improving their cell
adhesion properties, which are inherently relatively poor.
Due to its polyether backbone structure, PEG can only be
end-functionalized, in contrast to the above-mentioned
PHPMA/PHEMA-based hydrogels in which the radical
polymerization process allows introduction of reactive
monomers for peptide introduction along the backbone. In
this regard, the group of Langer developed an interesting
strategy for hydrogel synthesis and peptide incorporation,
relying on theMichael addition based reactions between 3-
arm thiol-terminated PEG and diacrylate terminated one
[37]. The introduction of an oligolysine peptide presenting
thiol-containing cysteine end residues (N- and C-terminus)
during this process led to successful peptide functionali-
zation of the hydrogel (Fig. 2A), which was shown to pro-
mote cell adhesion in a concentration dependent manner.
The oligolysine was here chosen as a ‘proof of concept’
model adhesion peptide. In further studies, Shepard et al.
similarly reported PEG-based hydrogels functionalized
with both RGD and oligolysine peptides [38]. In this case,
the oligolysine residues were used as afﬁnity peptides to
deliver a gene encoding for the nerve growth factor (NGF),
through electrostatic interactions between the cationiclysine residues and the negatively charged plasmid DNA
gene. The hydrogel was formed on the same basis of
Michael addition, by reaction of the free thiols of cysteine
residues of mono-functional or tri-functional peptides with
unsaturated vinyl-sulfone moieties present at the chain
ends of a 4-arm PEG. The functionalized hydrogel was
shown to be efﬁcient at retaining the DNA plasmid and
promoted improved neurite outgrowth, as a result of the
expression of the inductive NGF protein. More recently,
Anseth et al. designed in a very nice study PEG hydrogels
functionalized with RGD and YIGSR adhesion peptide se-
quences, using UV-initiated radical thiol-ene chemistry
[39]. The approach relied on the reaction of vinyl group of
norbornene moieties present on 4-arm PEG end-chains
with (i) thiol functions at both extremities of a peptide
(MMP-degradable sequence or oligolysine), for inducing
cross-linking, and (ii) thiol functions of the cysteine end
residues of CRGD and CYIGSR adhesion peptides (Fig. 2B).
The strategy resulted in robust extension of motor axons,
from a culture of mouse embryonic stem cell-derived
motor neurons (ESMNs). Finally, very recently, an alterna-
tive chemical approach based on azide/alkyne click chem-
istry and microwave-assisted synthesis was reported to
prepare agarose-polyacrylic acid (Carbomer)-PEG (ACPEG)
based hydrogels functionalized with RGD [40]. This method
involved a copper catalyzed azide/alkyne cycloaddition
(CuAAC) click reaction between the RGD azide derivative
and polyacrylic acid (PAA)- and PEG-modiﬁed alkynes.
Fig. 2. Chemical approaches for PEG-based hydrogel functionalization with cell adhesion peptides; (A) through Michael addition based reactions; (B) through
UV-initiated thiol-ene chemistry.
T. Trimaille et al. / C. R. Chimie 19 (2016) 157e166 161Cross-linking then occurred through microwave-assisted
polycondensation reactions of the carboxylic groups of
PAA-RGD with the hydroxyl groups of agarose and
hydroxyl-end group of PEG-RGD. However, the effect of this
hydrogel on cell survival has not yet been studied.
Besides these polymer-based hydrogels, original
studies have focused on self-assembled peptide hydro-
gels. Berns et al. have particularly developed peptide
amphiphiles (PAs) based on a hydrophobic polmitoyl
moiety attached to a hydrophilic peptide containing an
adhesion-promoting sequence [41]. These compounds,
namely palmitoyl-VVAAEEEEGIKVAV and palmitoyl-
VVAAEERGDS, were obtained through the reaction of
palmitic acid with N-terminus of the peptide segment as
a last step of the solid phase peptide synthesis (SPPS).
Self-assembly of these PAs in water led to hydrogels
made of aligned peptide nanoﬁbers over macroscopic
length scales. These RGD and IKVAV based hydrogels
were found to induce an enhanced neurite growth
from neurons (encapsulated in the gel), as compared to
the hydrogels made from the scrambled PA analogs
(namely palmitoyl-VVAAEEEEGVVIAK and palmitoyl-
VVAAEERSDG), unambiguously showing the positive
impact of the adhesion peptide sequence. Additionally,
the alignment guided the neurite growth along the di-
rection of the nanoﬁbers. Scaffolds encapsulating neural
progenitor cells were formed in situ within the spinal
cord and resulted in the growth of oriented processes
in vivo.3. Drug delivering hydrogels
Numerous drugs have been identiﬁed in the past few
years to have a valuable therapeutic potential for SCI.
Basically, their actions aim to favor axonal regeneration,
cellular survival and to reduce glial scar formation [42]. The
direct promotion of neuronal survival, neurite outgrowth
and synaptic formation can be induced by various neuro-
trophic factors such as among others, brain derived neu-
rotrophic factor (BDNF), neurotrophin-3 (NT-3), glial cell
line-derived neurotrophic factor (GDNF) and nerve
growth factor (NGF) [43]. Another strategy is to reduce the
effect of neurite outgrowth inhibitors that are generally
myelin-associated molecules like myelin-associated glyco-
protein (MAG), oligodendrocyte myelin glycoprotein
(OMgp) and Nogo-66 [44]. For example, the intrathecal
administration of NEP1-40 (i.e., Nogo-66 antagonist pep-
tide) promoted axonal regrowth and functional improve-
ment in rats after a spinal cord hemisection [45]. Enhancing
axonal regeneration can also be achieved by limiting the
steric hindrance of chondroitin sulfate proteoglycans
(CSPGs) through the use of chondroitinase ABC [46, 47].
Recent studies have particularly focused on an anti-glial
scarring drug strategy, since it has been shown to be of
crucial importance to promote functional recovery after
neural injury. Several teams have particularly pointed out
the potential of adenosine-based molecules for limiting
glial scar formation and promoting axonal regrowth
[48e51].
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in conventional ways (e.g. systemic injection) is generally
largely compromised by the rapid bloodstream clearance,
the lack of targeting of the injured tissue and the presence
of the blood-spinal cord barrier (BSCB). Similarly, drug-
loaded nano-carriers (e.g. biodegradable nanoparticles),
that have been shown to selectively target the lesion site
and to bring substantial improvements [52], still present a
limited efﬁciency that is frequently due to inadequate drug
release from the nanoparticles or the difﬁculty to cross the
BSCB [53]. As for local delivery through intrathecal injec-
tion, it is not really satisfactory because of rapid clearance
due to cerebrospinal ﬂuid ﬂow in the intrathecal space, and
the necessity of repeated doses, which poses the problem
of recurrent infections. Thus, the use of the hydrogel plat-
form for local and sustained delivery of drugs has appeared
as a valuable approach to overcome such limitations and
has gained increasing attention in recent research in SCI.
3.1. Controlled release of physically entrapped drugs
The potential of the hydrogel depot strategy for tunable/
controlled release of drugs had been particularly high-
lighted in pioneer studies of Shoichet's group, who
designed a hyaluronan/methyl cellulose (HAMC) based
hydrogel loaded with a cocktail of drugs (having comple-
mentary therapeutic action, e.g. neuroregenerative and
neuroprotective) encapsulated or not in biodegradable
poly(lactide-co-glycolide) (PLGA) nanoparticles [48, 54].
They showed that the time range of drug release could be
tuned so as to be adapted for neuroprotective and neuro-
regenerative treatments. In particular, neuroprotective
molecules, for which fast release is desirable, could be
released within 4 days by direct loading in the hydrogel,
whereas release of neuroregenerative molecules could be
extended over 28 days through encapsulation in PLGA
particles loaded in the gel. Interestingly, they also showed
that the prejudicial burst release effect classically observed
from particles alone was strongly reduced upon particle
loading in the gel, allowing a longer and more linear drug
release proﬁle.
Similarly, Sellers et al. showed in a recent study that
Pluronic F127-based hydrogel encapsulating anti-thrombin
agent-loaded PLGA nanoparticles enabled a controlled drug
release and a limited initial burst release as compared to
what has been observed with hydrogel and nanoparticles
alone [55]. These authors chose the use of an anti-thrombin
agent (hirudin), as it is long known that it may suppress
inﬂammation and scar formation [56]. They showed that
the controlled delivery of hirudin accelerated functional
recovery following lateralized demyelination lesion in the
mouse spinal cord.
Interesting results have also recently been obtained by
Rossi's team on hydrogel-nanoparticle composite systems
regarding the ability to ﬁnely tune the release of drugs,
using polyacrylic acid/agarose based hydrogels and pol-
y(methyl methacrylate) (PMMA) nanoparticles [57].
Indeed, the authors demonstrated the beneﬁcial outcomes
of nanoparticle drug encapsulation by conﬁrming the
prolonged release and the strongly reduced burst effect of
Rhodamine, which is a model drug with similar sterichindrance as anti-inﬂammatory drugs. The authors have
then further studied the in vitro release of different sized
nanoparticles (60, 80 and 130 nm) from several entangled
hydrogels (30, 60 and 90 nm mesh size). They showed that
the diffusion-controlled release of the nanoparticles was
highly dependent on nanoparticle size, and to a very less
extent on hydrogel mesh size. Indeed, after the intrathecal
injection of 2 composites of different sized nanoparticles
(60 and 130 nm), a faster nanoparticle release, in agree-
ment with the in vitro result, has been observed for the
smaller nanoparticles. These release/diffusion studies,
rationalized by mathematical modeling, are of high inter-
est regarding the design of biomaterial library able to
satisfy different drug delivery needs. Particularly, the au-
thors have further showed the potential of such
nanoparticle-loaded hydrogel for delivering pharmaco-
logical compounds in activated microglia/macrophages
thus counteracting relevant secondary inﬂammatory
events in SCI [58].
Other original research studies have been focused on
diblock copolypeptides (DCHs) as promising hydrogel
depots for sustained and controlled delivery of hydro-
phobic drugs in an injured spinal cord [59]. These block
copolypeptides consist of one long hydrophilic and
charged block composed of poly(L-lysine) and another
short block made of a hydrophobic amino acid sequence
(such as L-alanine, L-leucine, L-phenylalanine), and are
prepared by sequential ring-opening polymerization of
corresponding amino acid N-carboxyanhydride mono-
mers. These peptide-based architectures have been
proved to self-assemble at the nano-scale, through a so-
phisticated mechanism (association of the b-strands and
coiling of helices), resulting in hydrogel properties [60].
Interestingly, it was shown that different kinds of hy-
drophobic compounds can be loaded into DCH and
released over prolonged and controllable time frames,
and that both the loading capacity and release proﬁles
can be predictably, easily and ﬁnely tuned by adjusting
the hydrophobic block composition and DCH concentra-
tion in water. In addition, in vivo studies revealed that
DCH depots could deliver hydrophobic molecules
(tamoxifen) that alter gene expression of central nervous
system cells in a locally restricted and predicted manner
after injection into the forebrain or after a SCI. These non-
toxic peptide hydrogels are particularly interesting since
they were found to be biodegradable in vivo [61].
3.2. ‘Stimuli-responsive’ controlled release of covalently
entrapped drugs
Stimuli-responsive hydrogels are also very promising
systems for ﬁne tunable and ‘on-demand’ local drug de-
livery. In this regard, Shah et al. have developed a
remarkable photosensitive system composed of a photo-
triggerable drug conjugated silica nanoparticles encapsu-
lated within a PEG-based hydrogel [62]. The rationale
behind this strategy is to avoid passive and non-desired
diffusion/release of the drug that occurs in the classically
reported photo-responsive (e.g., photodegradable) hydro-
gels. Indeed, this system generally contains non-covalently
entrapped drugs that can slightly diffuse in the absence of
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ratio of drug release between the ‘on’ (light) and ‘off’ (no
light) state. The model drug was covalently attached to the
nanoparticles through an ortho-nitrobenzyl compound
linkage, known to induce a series of chemical rearrange-
ments upon photo-irradiation, which ultimately releases
the covalently bound drug. The drug-nanoparticle conju-
gate was then encapsulated in the hydrogel during its
chemical cross-linking through a click reaction between a
4-arm azide end-functionalized PEG and a di-alkyne func-
tionalized linear PEG in water. The potential of this system
has been demonstrated for delivery of a model drug to a
malignant cancer line, but it is clear that this hybrid scaffold
can be easily tuned for other soft tissue engineering/drug
delivery applications, such as SCI.
In another stimulus-based strategy, Chu et al. have
recently designed a HAMC hydrogel loaded with a PHPMA-
bivalirudin based polymer-peptide conjugate. Such a ma-
terial is able to release bivalirudin (i.e. an anti-thrombin
agent) via an enzyme-mediated process [63]. Indeed, the
grafted bivalirudin peptide (BM9) was designed to contain
an optimized matrix metalloproteinase-9 (MMP9) peptide
substrate linker (PRQITAG). The MMP9 was selected as the
target protease for triggering bivalirudin release due to its
maximal expression at 24 h following SCI. The conjugate
preparation consisted of three steps (i) Reversible Addition-
Fragmentation Chain Transfer (RAFT) copolymerization of
HPMA and N-(3-aminopropyl) methacrylamide hydro-
chloride (APMA), (ii) modiﬁcation of the pendant amine
groups of the prepared copolymer with a succinimidyl-4-
(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
difunctional agent, leading to the maleimide pendant
functions on the copolymer and (iii) coupling of the biva-
lirudin peptide on the PHPMA copolymer through thiol-
maleimide chemistry. This polymer conjugation approach
thus allowed an enzyme-mediated release upon MMP9
exposure, and a prolonged release from HAMC hydrogels
compared to the free bivalirudin peptide. Localized
administration of bivalirudin copolymers in vivo at the site
of rat SCI, in a contusion model, decreased cellular prolif-
eration and astrogliosis, suggesting that this bivalirudin
copolymer-hydrogel composite system could be a prom-
ising therapeutic tool for reducing immediate inﬂammatory
responses and long-term scarring.
4. Degradability
Although the most used synthetic polymer hydrogels
(e.g. PHEMA, PHPMA, and PEG) present very interesting
features, such as high water content, mechanical stability,
soft tissue similarities, and proving support for axonal
regeneration, they are non-degradable. Biodegradability is
a highly desirable property for any scaffold used in tissue
engineering applications, since it is expected to promote
tissue regeneration while gradually degrading so that only
host tissues remain. In non-degradable hydrogels, axonal
regrowth is unfortunately restricted to the existing pores of
the biomaterial [3]. Additionally, as these cross-linked
hydrogels cannot be cleared from the body, the calciﬁca-
tion and prolonged inﬂammatory response might limit
long-term axonal regeneration [64].Only few past studies have been dedicated to impart
biodegradability in these hydrogels. Regarding PEG-based
hydrogels, Piantino et al. proposed a versatile approach
based on the modiﬁcation of PEG-end groups with hy-
drolyzable lactide units terminated by a double bond
(acrylated lactide). The latter allowed radical photo-
polymerization and cross-linking using an appropriate
photo-initiator [65]. Regarding PHEMA-based hydrogels,
Atzet et al. reported an approach consisting of polymer-
izing HEMA in the presence of degradable oligocapro-
lactone diacrylate as a cross-linker, through an atom
transfer radical polymerization (ATRP) process initiated by
an oligocaprolactone di-bromide [66]. In the above-
mentioned systems, the hydrogel degradation is induced
by hydrolytic cleavage of ester containing units (lactide,
caprolactone), leading to recover individual polymer
chains, which can be cleared from body through renal
clearance if present in a sufﬁciently low molecular weight.
Rather than this hydrolytic-based process, interesting
alternative strategies relying on enzymatic degradation
have been very recently developed. Wang's team has, for
example, developed PEG-based copolymers containing
polyurethane segments (poly(serinol hexamethylene ure-
thane)) [67]. The latter allowed enzymatic degradation of
the hydrogel in the presence of cholesterol esterases. They
showed, in a spinal cord contusion model, that trans-
plantation of bone marrow stromal cells (BMSCs) in
hydrogel enhanced cell survival and led to superior loco-
motor and sensory-motor recovery [68]. In another study,
Jones et al. reported the preparation of PEG hydrogels
containing a collagenase-sensitive peptide, allowing for
hydrogel degradation in the ECM microenvironment [69].
Identically as described in the ﬁrst section, the cross-
linked hydrogel was prepared from Michael addition re-
actions between a 4-arm PEG acrylate and a thiol-
terminated peptide as a cross-linker (cysteine at N- and
C-terminus) [37]. In a similar chemical approach, based on
thiol-ene chemistry, Anseth et al. introduced matrix met-
alloproteinase (MMP) degradable peptides in their PEG
hydrogels, which had a beneﬁcial impact on the axon
outgrowth, by allowing the neurons to remodel their
extracellular environment [39].
Aliphatic polyesters such as polylactic acid (PLA) and
polycaprolactone are interesting biomaterials regarding
tissue engineering applications, due to their biodegrad-
ability and recognized biocompatibility [70]. However,
such biomaterials are too rigid to be implanted into soft
neural tissues as they are. Therefore, in a very recent study,
we synthesized a PLA-b-PHEMA block copolymer hydrogel
in order to beneﬁt from the complementary properties of
PHEMA and PLA that are, respectively, softness and de-
gradability [71]. We opted for a block copolymer design, as
a physical blending of the two incompatible homopoly-
mers would only result in a non-valid biomaterial dis-
playing a macrophase separation. Our synthesis approach,
based on a previous work realized in our laboratory [72,
73], relied on the use of a PLA-SG1 (N-tert-butyl-N-(1-
diethylphosphono-2,2-dimethylpropyl)aminoxyl) macro-
alkoxyamine. Such a molecule is able to initiate polymer-
ization of HEMA (Scheme 1) through nitroxide-mediated
polymerization (NMP), which is usually used as a
Scheme 1. Chemical pathway for preparation of the PLA-b-PHEMA block copolymer through ROP/NMP combination (SG1 ¼ ON(tBu)CH(tBu)PO(OEt)2).
T. Trimaille et al. / C. R. Chimie 19 (2016) 157e166164controlled/living radical polymerization technique [74, 75].
The PLA-SG1 was prepared from the intermolecular
radical addition of the MAMA-SG1 (BlocBuilder®) alkoxy-
amine onto acrylate end-capped PLA previously prepared
by ring-opening polymerization (ROP).
Through an in vitro study, we conﬁrmed that our PLA-b-
PHEMA (65/35%w) block copolymer was degradable, as
shown by its mass loss over time (Fig. 3), and supported
embryonic rat spinal motoneuron survival and neurite
outgrowth. Interestingly, the block copolymer could be
processed in a porous tridimensional hydrogel, without the
need for any cross-linking agent [76], using a versatile and
eco-friendly freeze-extraction process, requiring only
dimethyl sulfoxide as an organic solvent for block copol-
ymer dissolution, and water for extraction. Once the scaf-
fold is obtained, we implanted it in a hemisected rat spinal
cord cavity and observed an axonal regeneration into the
hydrogel 8 weeks post-injury (Fig. 4A) and a functional
recovery by the use of the Basso, Beattie and BresnahanFig. 3. PLA-b-PHEMA block copolymer’s mass loss (expressed as a per-
centage of its initial mass) as a function of time. While the block copolymer
maintained a constant mass over the ﬁrst 55 days, an increasing mass loss
was observed after that period. Indeed, the mass loss reached about 60%
after 97 days, consistent with the escape of most part of the PLA degradation
residues. Reproduced from Ref. [71] with permission from Elsevier.(BBB) test, which is a well-known locomotor rating scale
(Fig. 4B) [77]. Indeed, although the hydrogel-implanted
group did not fully recover, a superior functional
improvement has been detected compared to non-treated
hemisected rats. Other recent studies on aliphatic
polyester-based biomaterials for spinal cord repair consist
of increasing polymer ﬂexibility through introduction of
trimethylene carbonate (TMC) units along aliphatic poly-
esters [78]. In a further study, it was demonstated that a
poly(trimethylene carbonate-co- 3-caprolactone) (P(TMC-
CL)) copolymer signiﬁcantly promote axonal growth [79].
Interestingly, Xing et al. showed the possibility of chemical
derivatization of the TMC monomer with bioactive mole-
cules, such as acetylcholine analog. After copolymerization
of this TMC modiﬁed-monomer with lactide in various
proportions, the obtained copolymers promoted neurite
outgrowth in a concentration dependent manner [80].5. Conclusion
In this short review, we exposed the latest chemical
strategies that have been developed to potentiate the key
properties of synthetic hydrogels intended to be implanted
after SCI. By taking proﬁt of the synthetic polymer versa-
tility, several authors improved the hydrogel integration
and neurite outgrowth via the coupling of proteins and
peptides onto the hydrogel’s surface. Other efforts were
devoted to tuning drug release by embedding drug-loaded
nanoparticles into the hydrogel, or using relevant stimulus
(light, enzyme) responsive hydrogels. Moreover, hydrolyz-
able and enzyme-sensitive degradable hydrogels were
developed so as to avoid chronic complications and to ﬁt
with the axon regeneration process.
However, combining all desired characteristics (e.g.
biocompatibility, bioadhesion, porosity and degradability)
into a single therapeutically efﬁcient biomaterial is com-
plex. For example, it was previously shown that the
biomaterial degradation alters its three-dimensional
structure that, in turn, affects its capacity to induce
Fig. 4. Therapeutic effect induced by the implantation of our PLA-b-PHEMA hydrogel after a spinal cord hemisection. (A) Histological analyses, combining nuclear
staining (blue) and axonal marker (red), in the hydrogel region of implanted rats (Scale bar: 20 mm). (B) BBB locomotor rating score. Signiﬁcant differences in the
BBB scores are indicated by * (Hemisected rats pre-injury vs. Hemisected post-injury), þ (Implanted rats pre-injury vs. Implanted rats post-injury), d (Control rats
vs. Hemisected and Implanted rats) and U (Hemisected rats vs. Implanted rats) (One symbol p < 0.05 and 3 symbols p < 0.001). Adapted from Ref. [71] with
permission from Elsevier.
T. Trimaille et al. / C. R. Chimie 19 (2016) 157e166 165axonal regrowth [81]. Therefore, those interdependent
characteristics require compromises in the search of the
ideal scaffold.
Nevertheless, although clinical trials are not yet
conceivable, highly tunable synthetic hydrogels seem to be
a perfectly ﬁtted platform for promising combinatory
strategies.
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